Han Kun Law Offices

Legal Services | Hong Kong, China
tel: 00852 2820 5600 | fax: 00852 2820 5611
Rooms 3901-05, 39/F., Edinburgh Tower, The Landmark, 15 Queen’s Road Central | Hong Kong | Hong Kong | China

Main Contacts



Han Kun is a leading full-service law firm in China. Over the years, Han Kun has been widely recognized as a leader in complex cross-border and domestic transactions and compliance matters.

Our main practice areas include private equity, mergers and acquisitions, international and domestic capital markets, investment funds, asset management, compliance, banking and finance, aviation finance, foreign direct investment, antitrust/competition, data protection, private client/wealth management, intellectual property and dispute resolution.

We have nearly 800 professionals located in our seven offices in Beijing, Shanghai, Shenzhen, Hong Kong, Haikou, Wuhan, as well as Singapore, a leading financial center in the Asia-Pacific. All our lawyers are graduates of top universities and have extensive experience in complex cross-border transactions and dispute resolution as counsel to both Chinese and foreign clients.

Lawyers Worldwide: 800

Areas of Practice


Of Counsel

JIA(Jenny)  Li

JIA(Jenny) Li

Of Counsel
Jiankun(Rio)  Li

Jiankun(Rio) Li

Of Counsel


The New U.S. Executive Order Compounds Compliance Dilemmas

On 9 August 2023, U.S. President Joe Biden signed the Executive Order on Addressing United States Investments in Certain National Security Technologies and Products in Countries of Concern (the "Executive Order"), to regulate U.S. persons engaged in transactions or investment activities in China (including mainland China, Hong Kong and Macau) that involve certain technologies and products. The U.S. Department of the Treasury (the "Department of Treasury") issued on the same day an Advance Notice of Proposed Rulemaking (the "ANPRM") to seek public comments in formulating the regulations to implement the Executive Order and to clarify its scope...

China DCT Regulation and Implementation

The concept of "patient-centered" has become the core guiding principle in current research and development ("R&D") of drugs. "Patient-centered" drug R&D refers to the process of drug discovery, design, implementation and decision-making based on the patient's point of view, with the aim of efficiently developing clinically valuable drugs that better meet the needs of patients. Decentralized Clinical Trials ("DCT") are a new type of clinical trial that embodies the "patient-centered" concept, providing new solutions and motivation for drug R&D activities for marketing registration purposes...

VIEW ALL Han Kun Law Offices Articles


Han Kun authors the China Chapter of The Virtual Currency Regulation Review (6th edition)

The well-known London-based legal publisher Law Business Research recently published its sixth edition of The Virtual Currency Regulation Review (The Virtual Currency Regulation Review: 6th edition). As the only invited PRC law firm, Han Kun has authored the Virtual Currency Regulation Review for two consecutive years. Han Kun's financial services and asset management partner Mr. TieCheng Yang, counsel Mr. Meng (Raymond) Yan and associate Ms. Wenli (Ivy) Xu co-authored the China Chapter. The intern Ms. Peixi (Regina) Gong also contributed to the writing of the China Chapter...

Han Kun shortlisted in 18 award categories for IFLR1000 China Awards 2023

On September 14, 2023, IFLR1000 announced the shortlist for its China Awards 2023. Han Kun was nominated in 18 award categories, including: Capital Markets Team of the Year M&A Team of the Year Firm of the Year – Guangdong Banking and Finance Deal of the Year – Beijing - COMAC delivered its first-ever C919 airliner to China Eastern Airlines Capital Markets Deal of the Year - Beijing – KE Holdings’ Hong Kong dual-primary listing Capital Markets Deal of the Year - Beijing – NIO’s listing by introduction in HK, Singapore M&A Deal of the Year – Beijing – ByteDance’s USD1...

VIEW ALL Han Kun Law Offices Press